DHA-LPC Brain Delivery via Blood-Barrier Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for supplementing with omega-3 fatty acids, such as DHA and EPA, face challenges in delivering these essential fatty acids effectively to the brain, where they are needed for neurological health, due to issues with absorption and availability.
Innovation Solution
The development of DHA- or EPA-containing phospholipid compounds, specifically in the form of lysophosphatidylcholine (LPC), which are incorporated into micelles or vesicles, providing a more efficient molecular carrier that can cross the blood-brain barrier, increasing brain levels of these fatty acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional omega-3 supplementation methods are used, then omega-3 fatty acids are provided to the body, but their delivery to the brain is insufficient due to poor absorption and availability
Solution Approach 1:
The patent uses phospholipids (specifically lysophosphatidylcholine or LPC) as intermediary molecules to carry omega-3 fatty acids (DHA and EPA) across the blood-brain barrier. These phospholipid carriers act as mediators that facilitate the transport of omega-3s from the bloodstream into brain tissues, overcoming the limitation of poor direct absorption and delivery to the brain.
2Quantity of substance
If DHA and EPA are supplemented in conventional forms, then the body receives these fatty acids, but brain tissue incorporation is limited
Solution Approach 1:
The patent changes the molecular form or parameter of omega-3 delivery by incorporating DHA and EPA into phospholipid structures (specifically at the sn-2 position of LPC). This structural modification enables the fatty acids to be recognized and transported by specific brain uptake mechanisms, dramatically improving incorporation efficiency into brain tissues compared to conventional free fatty acid or triglyceride forms.
Data Source
AI summary
Described herein are at least compounds and formulations that can be or contain a docosahexaenoic acid-lysophosphatidylcholine (DHA-LPC) and/or eicosapenteanoic acid-lysophosphatidylcholine (EPA-LPC). Also described herein are at least methods of making and using the compositions and formulations DHA-LPC and/or EPA-LPC.